Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7283420
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
RO7283420 is a bispecific monoclonal antibody designed to engage T cells for the targeted killing of leukemia cells. It simultaneously binds to CD3 on cytotoxic T lymphocytes and to a complex of HLA-A2 presenting the WT1 peptide on leukemia cells, thereby redirecting T cell cytotoxicity toward malignant cells expressing this target. The drug is being developed by Hoffmann-La Roche for the treatment of relapsed or refractory acute myeloid leukemia (AML). Its mechanism leverages immune system activation against cancer by bridging effector and target cells, representing an innovative approach in immuno-oncology[1][2][7][8].
- Other names
- anti-HLA-A2-WT1/anti-CD3 T-cell engaging bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on RO7283420.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7283420.